

Case No. 033.07

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Singh

Serial No: 09/824,905

Filed: 02 April 2001

For: KITS EMPLOYING
OLIGONUCLEOTIDE-BINDING
E-TAG PROBES

Examiner: J. Tung

Art Unit: 1656


**TERMINAL DISCLAIMER UNDER
37 C.F.R. 1.321©**Assistant Commissioner of Patents
Washington, D. C. 20231

Sir:

The owner, Aclara Biosciences, Inc., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 09/825,245, filed on 02 April 2001, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent granted, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

The undersigned is an attorney or agent of record.


Stephen C. Macevitz
Reg. No. 30,285July 15, 2002
Date

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

07/25/2002 MGRAVES 00000003 502266 09824905

01 FC:248

55.00 CH

Case No. 033.07

#151 TD
max
7/24/02IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Singh

Serial No: 09/824,905

Filed: 02 April 2001

For: KITS EMPLOYING
OLIGONUCLEOTIDE-BINDING
E-TAG PROBES

Examiner: J. Tung

Art Unit: 1656

TERMINAL DISCLAIMER UNDER
37 C.F.R. 1.321©Assistant Commissioner of Patents
Washington, D. C. 20231

Sir:

The owner, Aclara Biosciences, Inc., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 09/825,246, filed on 02 April 2001, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent granted, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

The undersigned is an attorney or agent of record.


Stephen C. MacevitzJuly 15, 2002
Date

Reg. No. 30,295

07/25/2002 MGRAVES 00000004 502266 09824905

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

01 FC:248

55.00 CH

#16/TD
max
7/24/02

Case No. 033.07

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Singh

Serial No: 09/824,905

Filed: 02 April 2001

For: KITS EMPLOYING
OLIGONUCLEOTIDE-BINDING
E-TAG PROBES

Examiner: J. Tung

Art Unit: 1656


TERMINAL DISCLAIMER UNDER
37 C.F.R. 1.321©Assistant Commissioner of Patents
Washington, D. C. 20231

Sir:

The owner, Aclara Biosciences, Inc., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 09/824,861, filed on 02 April 2001, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent granted, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

The undersigned is an attorney or agent of record.


Stephen C. Macevitz
Reg. No. 30,285July 15, 2002
Date

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

07/25/2002 MGRAVES 580000006 582266 09824905

Case No. 033.07

7/24/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Singh

Serial No: 09/824,905

Filed: 02 April 2001

For: KITS EMPLOYING
OLIGONUCLEOTIDE-BINDING
E-TAG PROBES

Examiner: J. Tung

Art Unit: 1656


TERMINAL DISCLAIMER UNDER
37 C.F.R. 1.321©Assistant Commissioner of Patents
Washington, D. C. 20231

Sir:

The owner, Aclara Biosciences, Inc., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 09/824,851, filed on 02 April 2001, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent granted, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

The undersigned is an attorney or agent of record.


Stephen C. Macevlcz
Reg. No. 30,285July 15, 2002
Date

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

07/25/2002 MGRAVES 00000005 502266 09824905

01 FC:248

55.00 CH